Scientific Reports (Jan 2023)

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages

  • Jinal N. Bhiman,
  • Simone I. Richardson,
  • Bronwen E. Lambson,
  • Prudence Kgagudi,
  • Nonkululeko Mzindle,
  • Haajira Kaldine,
  • Carol Crowther,
  • Glenda Gray,
  • Linda-Gail Bekker,
  • Novavax trial clinical lead author group,
  • Vivek Shinde,
  • Chijioke Bennett,
  • Gregory M. Glenn,
  • Shabir A. Madhi,
  • Penny L. Moore

DOI
https://doi.org/10.1038/s41598-023-27698-x
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 5

Abstract

Read online

Abstract The SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern (VOC) and its sub-lineages (including BA.2, BA.4, BA.5, BA.2.12.1) contain spike mutations that confer high level resistance to neutralizing antibodies induced by vaccination with ancestral spike or infection with previously circulating variants. The NVX-CoV2373 vaccine, a protein nanoparticle vaccine containing the ancestral spike sequence, has value in countries with constrained cold-chain requirements. Here we report neutralizing titers following two or three doses of NVX-CoV2373. We show that after two doses, Omicron sub-lineages BA.1 and BA.4/BA.5 were resistant to neutralization by 72% (21/29) and 59% (17/29) of samples respectively. However, after a third dose of NVX-CoV2373, we observed high titers against Omicron BA.1 (GMT: 1,197) and BA.4/BA.5 (GMT: 582), with responses similar in magnitude to those triggered by three doses of an mRNA vaccine. These data are of particular relevance as BA.4/BA.5 is dominating in multiple locations, and highlight the potential utility of the NVX-CoV2373 vaccine as a booster in resource-limited environments.